Drugs / MDX-1203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00944905 | Jul 2009 → Nov 2012 | non-Hodgkin lymphoma, renal cell carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDX-1203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00944905 ↗ |
| Modality | Monoclonal antibody | “a fully human monoclonal antibody drug conjugate” NCT00944905 ↗ |
| Route | Intravenous | “MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion” NCT00944905 ↗ |
| Target | CD70 | “targeting the CD70 transmembrane cell-surface protein” NCT00944905 ↗ |